• Users Online: 466
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
CLINICAL QUERIES
Year : 2016  |  Volume : 14  |  Issue : 4  |  Page : 84-85

Clinical questions: Responses to queries from readers: Benign Prostatic Hypertrophy


Professor, Department of Urology, CMC, Vellore, India

Date of Web Publication22-Nov-2016

Correspondence Address:
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-4651.194455

Rights and Permissions

How to cite this article:
Nirmal T J. Clinical questions: Responses to queries from readers: Benign Prostatic Hypertrophy. Curr Med Issues 2016;14:84-5

How to cite this URL:
Nirmal T J. Clinical questions: Responses to queries from readers: Benign Prostatic Hypertrophy. Curr Med Issues [serial online] 2016 [cited 2019 May 26];14:84-5. Available from: http://www.cmijournal.org/text.asp?2016/14/4/84/194455

Question 4

What
is the role of sildenafil in benign prostatic hyperplasia?

Answer:


Phosphodiesterase 5 inhibitors (PDE5i) such as sildenafil and tadalafil increase intracellular cyclic guanosine monophosphate resulting in a reduction of smooth muscle tone of the detrusor, prostate, and urethra resulting in improvement of lower urinary tract symptoms (LUTSs) related to benign prostatic hyperplasia (BPH). [1] In a meta-analysis, PDE5is have been shown to improve both voiding and storage LUTS (IPSS score) and erectile function (IIEF score) but not urinary flow rate (Qmax). [2] However, a combination of PDE5is and α-blockers (e.g., Tamsulosin) has been shown to improve flow rate as well. [2]

Despite several PDE5is showing efficacy in randomized control trials, only tadalafil (5 mg once daily) and not sildenafil has been approved for the treatment of moderate to severe male LUTSs with or without erectile dysfunction. PDE5is are contraindicated in patients using nitrates. They are also contraindicated in patients who have unstable angina pectoris, have had a recent myocardial infarction (<3 months) or stroke (<6 months), and myocardial insufficiency (New York Heart Association stage >2).

 
  References Top

1.
Giuliano F, Ückert S, Maggi M, Birder L, Kissel J, Viktrup L. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013;63:506-16.  Back to cited text no. 1
    
2.
Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.  Back to cited text no. 2
    




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References

 Article Access Statistics
    Viewed667    
    Printed47    
    Emailed0    
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]